To halt brain diseases, drugs take aim at protein traffic jams that kill neurons
Elie Dolgin • January 16, 2019
Compound that normalizes flow of proteins in cells will now be tested in a clinical trial for ALS
Continue reading at Science Magazine.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.